KRAS and lung adenocarcinoma: ‘Exclusivity plots’ for COAD revealed mutations in BRAF to be negatively associated with mutations in KRAS, to a degree similar to that we observed for co-existing mutations of EGFR and KRAS in lung adenocarcinoma (Figure 1F).